These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30387238)

  • 1. Online accounts of gene expression profiling in early-stage breast cancer: Interpreting genomic testing for chemotherapy decision making.
    Ross E; Swallow J; Kerr A; Cunningham-Burley S
    Health Expect; 2019 Feb; 22(1):74-82. PubMed ID: 30387238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unsettling the treatment imperative? Chemotherapy decision-making in the wake of genomic techniques.
    Ross E; Kerr A; Swallow J; Chekar CK; Cunningham-Burley S
    Sociol Health Illn; 2023 Jun; 45(5):1063-1081. PubMed ID: 36965058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
    El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
    Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
    Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
    Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
    Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
    Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer.
    Havard R; Henry NL
    Future Oncol; 2017 Dec; 13(28):2507-2510. PubMed ID: 29168654
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
    Marshall DA; Deal K; Bombard Y; Leighl N; MacDonald KV; Trudeau M
    BMJ Open; 2016 Jun; 6(6):e010981. PubMed ID: 27256091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
    Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
    Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
    Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
    Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncotype DX
    Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
    Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge about genomic recurrence risk testing among breast cancer survivors.
    Lipkus IM; Vadaparampil ST; Jacobsen PB; Miree CA
    J Cancer Educ; 2011 Dec; 26(4):664-9. PubMed ID: 21688183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
    MacDonald KV; Bombard Y; Deal K; Trudeau M; Leighl N; Marshall DA
    Eur J Cancer; 2016 Jul; 61():85-93. PubMed ID: 27155447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
    Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
    Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of PONDx, a prospective multicenter study of the Oncotype DX
    Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
    Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-expression Profiling - A Decision Impact Analysis: Decision Dependency on Oncotype DX® as a Function of Oncological Work Experience in 117 Cases.
    Eichler C; Fromme J; Thangarajah F; Puppe J; Paepke S; Warm M; Malter W
    Anticancer Res; 2019 Jan; 39(1):297-303. PubMed ID: 30591472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
    Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
    Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.